Data as filed with the SEC, provided for information only — not investment advice.
Financial data temporarily unavailable. Try again in a few moments.
Who is buying and selling bioAffinity Technologies, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on BIAF yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on BIAF and publish the result to your public profile.
Ask about bioAffinity Technologies, Inc.
Continue in Workspace — cited answers on BIAF, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001493152-26-036619 | Jun 30, 2026 | Aug 7, 2026 | Aug 7, 2026 20:45 UTC | EDGAR |
| 10-Q | 0001493152-26-022044 | Mar 31, 2026 | May 11, 2026 | May 8, 2026 22:27 UTC | EDGAR |
| 10-K | 0001493152-26-010143 | Dec 31, 2025 | Mar 16, 2026 | Mar 14, 2026 01:50 UTC | EDGAR |
| 10-Q | 0001493152-25-023405 | Sep 30, 2025 | Nov 14, 2025 | Nov 14, 2025 21:02 UTC | EDGAR |
| 10-Q | 0001641172-25-024163 | Jun 30, 2025 | Aug 14, 2025 | Aug 14, 2025 21:07 UTC | EDGAR |
| 10-Q | 0001641172-25-010787 | Mar 31, 2025 | May 15, 2025 | May 15, 2025 19:33 UTC | EDGAR |
| 10-K/Aamend | 0001641172-25-006707 | Dec 31, 2024 | Apr 29, 2025 | Apr 29, 2025 21:29 UTC | EDGAR |
| 10-K | 0001641172-25-001840 | Dec 31, 2024 | Mar 31, 2025 | Mar 31, 2025 21:10 UTC | EDGAR |
| 10-Q | 0001493152-24-045954 | Sep 30, 2024 | Nov 14, 2024 | Nov 14, 2024 21:34 UTC | EDGAR |
| 10-Q | 0001493152-24-031943 | Jun 30, 2024 | Aug 14, 2024 | Aug 14, 2024 13:37 UTC | EDGAR |
| 10-Q | 0001493152-24-019615 | Mar 31, 2024 | May 15, 2024 | May 15, 2024 14:53 UTC | EDGAR |
| 10-K | 0001493152-24-012358 | Dec 31, 2023 | Apr 1, 2024 | Apr 1, 2024 20:06 UTC | EDGAR |
Direct links to SEC EDGAR. BIAF has additional filings available on the SEC site.
6 numbers bioAffinity Technologies, Inc. later changed — same XBRL tag, both filings linked.
Operating Expenses·Q3 2023
Notable restatementwas$2.5M
Revised up in a 10-Q.
Interest Paid, Excluding Capitalized Interest, Operating Activities·Q1 2023
Major restatementwas$1.7K
Revised up in a 10-Q.
Common Stock, Value, Issued·As of Dec 31, 2024
Major restatementwas$106.6K
Revised down in a 10-K.
Depreciation·Q3 2023
Major restatementwas$23.5K
Revised up in a 10-Q.
Lease, Cost·Q2 2024
Major restatementwas$148.4K
Revised up in a 10-Q.
Income Taxes Paid, Net·Q1 2023
Major restatementwas$11.8K
Revised down in a 10-Q.
BIAF is not the only one.
See every restatement we've found across the market — or get an alert the next time BIAF revises a number.
Restatements are detected by comparing every vintage of a fact across all of bioAffinity Technologies, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows BIAF's most significant revisions, and a figure absent from it has not been certified as unrevised.
